Brief: Natco Pharma Sept-Quarter Consol Revenue From Operations 13.63 Billion Rupees
14/11/2025 09:40
Nov 14 (Reuters) - Natco Pharma Ltd NATP.NS: SEPT-QUARTER CONSOL NET PROFIT 5.18 BILLION RUPEES SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 13.63 BILLION RUPEES DECLARES INTERIM DIVIDEND OF 1.50 RUPEE PER SHARE APPROVES WHOLLY-OWNED SUBSIDIARY FOR DEMERGER OF CROP HEALTH SCIENCES DIVISION Further company coverage: NATP.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees